N/A N=15 Mucinex® for Treatment of Filamentary Keratitis
Filamentary Keratitis
Primary: Change in Number of Corneal Filaments — 5.8; 2.1 corneal filaments — p=<0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
Persistent Corneal Epithelial Defect
Primary: Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 Weeks — 5 Participants
Phase 2 N=510 Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
Keratoconus · Post-Refractive Ectasia
Primary: Change in Maximum Keratometry From Baseline to 6 Months After Treatment — 0.76; 0.97 diopters
Phase 2 N=120 Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
N/A N=18 Corneal Topographer Fluorescein Patterns
Keratoconus
Primary: Number of Participants With an Observable Difference Between Virtual Versus Actual Fluorescein Patterns — 0 participants
Phase 3 N=70 Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
Phase 2 N=65 Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
Fuchs' Endothelial Corneal Dystrophy
Primary: Central Corneal Endothelial Cell Density (ECD) at Week 12 — 530.86; 468.02; 228.05 cells/mm2 — p=0.0065
Phase 3 N=147 Cross-linking for Corneal Ulcers Treatment Trial
Corneal Ulcer · Infectious Keratitis · Bacterial Ulcer
Primary: Microbiological Cure on Repeat Culture — 5; 5; 17; 14 Participants
Phase 2 N=1 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
Chemical Injuries · Unspecified Complication of Corneal Transplant · Autoimmune Diseases
Primary: Changes in Corneal Thickness at 1 Millimeter — 730; 760; 700; 720 micrometer
Phase 3 N=134 Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Acanthamoeba Keratitis
Primary: Clinical Resolution Rate — 84.8; 88.5 percentage of participants
Phase 3 N=147 Corneal Collagen Cross-linking for Progressive Keratoconus
Progressive Keratoconus
Primary: Mean Change From Baseline in Maximum Keratometry (Kmax) — -1.7; 0.6 diopters
N/A N=26 Keratometric Tear Breakup Time and Fluorescein Tear Breakup Time
Dry Eye
Primary: Difference Between Keratometric Tear Break Up Time (KTBUT) and Fluorescein Tear Break Up Time (FTBUT) — 5.95; 5.39 time in seconds — p=0.074
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 4 N=36 Impact of Acthar on Everyday Life of Participants With Severe Keratitis
Keratitis
Primary: Number of Participants Who Improved on the Impact of Dry Eye on Everyday Life (IDEEL) Scale [Using the Symptom Bother Module at Week 12] — 17 Participants
Phase 4 N=218 Daily Wear Corneal Infiltrative Event Study
Myopia · Hyperopia · Corneal Infiltrative Events
Primary: Number of Participants Developing a Corneal Inflammatory Event (CIE) — 6; 7 participants
Phase 3 N=323 Mycotic Ulcer Treatment Trial I
Corneal Ulcer · Eye Infections, Fungal
Primary: Best Spectacle-corrected logMAR Visual Acuity — 0.39; 0.57 logMAR — p=0.006
Phase 3 N=240 The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo
Corneal Ulcer · Eye Infections, Fungal
Primary: Incidence of Perforation or Therapeutic Penetrating Keratoplasty — 0.0095562; 0.011204 New perforations or TPK/person-days — p=0.29
Phase 3 N=239 Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
Progressive Keratoconus
Primary: Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax — -0.3; 0.6 Diopters — p=0.0004
Phase 2 N=68 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit
Keratolysis
Primary: Time From Surgery to Device Loss or Replacement — 95; 34 median weeks from surgery to removal
N/A N=40 Sutureless Cryopreserved Amniotic Membrane Graft (ProKera) and Wound Healing After Photorefractive Keratectomy
Corneal Wound Healing
Primary: Number of Days to Complete Re-epithelialization — 4.6; 4.1 days to complete re-epithelialization
Phase 4 N=17 Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis
Keratitis
Primary: Correlation Between the Change From Baseline in VMR Measured With FVA System at Month 3 and the Change From Baseline in the CFS at Month 3. — -0.7028 Spearman's…
N/A N=12 Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis
Atopic Keratoconjunctivitis
Primary: Ocular Symptoms and Signs Total Composite Score — 29.1; 4.7 units on a scale — p=0.002
Phase 2 N=141 Clinical Evaluation of Etafilcon A With Ketotifen
Visual Acuity
Primary: Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population) — -0.111; -0.109; -0.115; -0.118 logMAR
Phase 2 N=282 Mucin Balls and Corneal Inflammation Events
Corneal Inflammation · Corneal Infiltrative Events
Primary: Corneal Infiltrate Events - Phase I — 18.6; 5.7 percentage of subjects
Phase 3 N=350 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
Dry Eye Disease With Severe Keratitis
Primary: The Correlation Between Mean Change From Baseline in Corneal Fluorescein Staining (CFS) Score and Symptom Assessment iN Dry Eye (SANDE) Symptoms Score at Each Visit…
N/A N=30 Transepithelial Corneal Cross-linking Using Iontophoresis
Progressive Keratoconus
Primary: K-max — -0.52; -0.82 Diopters (D) — p=<0.05
N/A N=60 Clinical Performance of Stenfilcon A Versus Filcon II 3
Myopia
Primary: Daily and Comfortable Wearing Time — 9.8; 7.7 hours
N/A N=5 Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty
Corneal Ulcer · Leukoma
Primary: Incidence of Treatment-Emergent Adverse Events — 0 events
Phase 2 N=22 A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
Fuchs' Corneal Endothelial Dystrophy (FCED)
Primary: Incidence and Severity of Ocular TEAEs. — 3; 6; 1; 1 Participants
N/A N=94 Simultaneous TransPRK and Corneal Collagen Cross-Linking
Keratoconus
Primary: Change in LogMAR Corrected Distance Visual Acuity (CDVA) — -0.13; -0.05 LogMAR CDVA — p=0.03